ATE102830T1 - Methode zur behandlung des interstitiellen blasenentzuendung. - Google Patents

Methode zur behandlung des interstitiellen blasenentzuendung.

Info

Publication number
ATE102830T1
ATE102830T1 AT89311177T AT89311177T ATE102830T1 AT E102830 T1 ATE102830 T1 AT E102830T1 AT 89311177 T AT89311177 T AT 89311177T AT 89311177 T AT89311177 T AT 89311177T AT E102830 T1 ATE102830 T1 AT E102830T1
Authority
AT
Austria
Prior art keywords
treatment
bladder inflammation
naltrexone
nalmefene
interstitial bladder
Prior art date
Application number
AT89311177T
Other languages
English (en)
Inventor
Fred P Sherman
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Application granted granted Critical
Publication of ATE102830T1 publication Critical patent/ATE102830T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Threshing Machine Elements (AREA)
AT89311177T 1988-11-01 1989-10-30 Methode zur behandlung des interstitiellen blasenentzuendung. ATE102830T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/265,575 US4877791A (en) 1988-11-01 1988-11-01 Method of treatment for interestitial cystitis
EP89311177A EP0367533B1 (de) 1988-11-01 1989-10-30 Methode zur Behandlung des interstitiellen Blasenentzündung

Publications (1)

Publication Number Publication Date
ATE102830T1 true ATE102830T1 (de) 1994-04-15

Family

ID=23011021

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89311177T ATE102830T1 (de) 1988-11-01 1989-10-30 Methode zur behandlung des interstitiellen blasenentzuendung.

Country Status (11)

Country Link
US (1) US4877791A (de)
EP (1) EP0367533B1 (de)
JP (1) JPH07556B2 (de)
AT (1) ATE102830T1 (de)
AU (1) AU623189B2 (de)
CA (1) CA2001996C (de)
DE (1) DE68913907T2 (de)
DK (1) DK541189A (de)
HK (1) HK119994A (de)
NO (1) NO894295L (de)
ZA (1) ZA897823B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4994466A (en) * 1990-06-14 1991-02-19 Baker Cummins Pharmaceuticals, Inc. Method of treatment for multiple sclerosis
US5057322A (en) * 1990-08-10 1991-10-15 Baker Cummins Dermatologicals, Inc. Method of treating mast cell disease
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
ES2214532T3 (es) 1995-03-03 2004-09-16 Endo Pharmaceuticals Inc. Uso de dextrorfano o dextrometorfano para el tratamiento de la incontinencia urinaria.
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
WO2000044390A1 (en) * 1999-02-01 2000-08-03 John Lezdey Treatment of bladder and gastrointestinal mastocytosis
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
WO2002081477A1 (en) * 2001-03-30 2002-10-17 Toray Industries, Inc. 7-substituted morphinane derivatives and medicinal use thereof
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
DK2010220T3 (da) * 2006-04-03 2022-05-23 Ceva Animal Health Pty Ltd Stabiliserede pentosanpolysulfat-(pps)-formuleringer
US9844533B2 (en) * 2008-12-16 2017-12-19 Hill's Pet Nutrition, Inc. Antioxidant-containing food composition for use in inhibiting histamine pathways in companion animals
WO2019227053A1 (en) * 2018-05-25 2019-11-28 Adamis Pharmaceuticals Corporation Drug compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51145B1 (en) * 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
EP0245366A1 (de) * 1985-10-29 1987-11-19 Baker Cummins Pharmaceuticals, Inc. Verfahren und zusammensetzung zur blockierung der antigeninduzierten allergischen reaktionen
FR2609632B1 (fr) * 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases

Also Published As

Publication number Publication date
EP0367533B1 (de) 1994-03-16
DK541189D0 (da) 1989-10-30
DE68913907D1 (de) 1994-04-21
AU4385089A (en) 1990-05-10
AU623189B2 (en) 1992-05-07
NO894295D0 (no) 1989-10-27
EP0367533A3 (de) 1991-10-02
ZA897823B (en) 1990-07-25
NO894295L (no) 1990-05-02
EP0367533A2 (de) 1990-05-09
DE68913907T2 (de) 1994-06-23
JPH02188525A (ja) 1990-07-24
JPH07556B2 (ja) 1995-01-11
CA2001996C (en) 1996-07-23
US4877791A (en) 1989-10-31
HK119994A (en) 1994-11-11
CA2001996A1 (en) 1990-05-01
DK541189A (da) 1990-05-02

Similar Documents

Publication Publication Date Title
DE68916387D1 (de) Verwendung von Nalmefen oder Naltrexon bei der Behandlung von Autoimmunerkrankungen.
EP0377272A3 (de) Verwendung von Nalmefen oder Naltrexon zur Herstellung eines Arzneimittels zur Entzündungsbehandlung der Arthritis und assoziierter entzündlicher Erkrankungen
ATE102830T1 (de) Methode zur behandlung des interstitiellen blasenentzuendung.
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
PH23867A (en) Method of treating parkinson's disease using indolone derivatives
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
PT97785A (pt) Metodo para a tratamento da impotencia utilizando, por exemplo, doxazosina
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE69201660D1 (de) Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma.
ATE78687T1 (de) Quaternaere derivate von noroxymorphon zur behandlung von uebelkeit und erbrechen.
ES2093357T3 (es) Metodo de tratamiento de la alopecia.
DE69113921D1 (de) Verwendung eines reinen Opiatantagonisten, z.B. Nalmefen, Naltrexon, Naloxon oder Diprenorphin, zur Behandlung von Mastzell-Erkrankungen.
DE68910010D1 (de) Verwendung von Dapiprazol zur Herstellung eines Arzneimittels zur Verhinderung des Toleranzentwicklung bei der analgetischen Behandlung mit Morphin.
PH30028A (en) Treatment of anxiety in benzodiazepine withdrawn patients
UA30654A (uk) Спосіб лікування посттравматичних дисфункцій висково- нижньощелепового суглоба
ATE388706T1 (de) Die verwendung von wasserunlöslichem s- camptothecin mit geschlossenem lactonring für die herstellung eines medikamentes zur behandlung von darmkrebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee